Abstract

Diabetes mellitus affects over 537 million adults worldwide, with inadequate glycemic control contributing to 
significant morbidity and mortality despite advances in insulin therapy. Conventional insulin delivery systems faced 
limitations including frequent injections, poor patient adherence, hypoglycemic episodes, and suboptimal 
pharmacokinetic profiles that fail to mimic physiological insulin secretion patterns. Nanoparticle enabled insulin 
delivery systems represented a transformative approach to address these challenges through enhanced 
bioavailability, controlled release kinetics, and targeted delivery mechanisms. This review synthesized current 
literature from PubMed, Scopus, and Web of Science databases spanning 2012-2025, focusing on peer reviewed 
studies describing nanoparticle formulations for insulin delivery and their clinical applications. Recent innovations 
demonstrated significant improvements in glycemic control, with polymeric nanoparticles achieving sustained 
insulin release for 12-72 hours and oral delivery systems showing bioavailability improvements of 3-15-fold 
compared to conventional formulations. Lipid based nanocarriers, chitosan nanoparticles, and stimuli responsive 
systems exhibited promising pharmacokinetic profiles with reduced injection frequency and enhanced patient 
compliance. Current limitations include manufacturing scalability, regulatory approval pathways, and long-term 
safety assessment requirements. Nanoparticle insulin delivery systems offered substantial potential for 
revolutionizing diabetes management through improved therapeutic efficacy, patient compliance, and quality of life 
outcomes. The integration of glucose responsive nanosystems with continuous glucose monitoring represents the 
most promising pathway toward achieving physiological glucose homeostasis in diabetic patients. 
Keywords: Nanoparticle insulin delivery, Glycemic control, Diabetes mellitus, Oral insulin, Stimuli responsive 
systems.